Quick Answer
Matinas BioPharma Holdings, Inc. reported Revenue From Contract With Customer Excluding Assessed Tax of $1.10 million for the year ending 2023.
- Matinas BioPharma Holdings, Inc. showed a decrease of -65.6% in Revenue From Contract With Customer Excluding Assessed Tax from 2022 to 2023.
- This data is from Matinas BioPharma Holdings, Inc.'s annual report (Form 10-K), filed with the SEC on April 15, 2025.
- XBRL data for this metric is available from 2018 to 2023 (6 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Over the full 6 years of available data (2018 to 2023), Matinas BioPharma Holdings, Inc.'s Revenue From Contract With Customer Excluding Assessed Tax has grown by 815.2%.
- Historical annual values: Fiscal year 2023: $1.10 million | Fiscal year 2022: $3.19 million | Fiscal year 2021: $33.0 thousand | Fiscal year 2020: $158.3 thousand | Fiscal year 2019: $89.8 thousand | Fiscal year 2018: $119.8 thousand.
- Data sourced from SEC EDGAR public filings as of June 23, 2026.
Last verified: